Platelet Signaling in Primary Haemostasis and Arterial Thrombus Formation: Part 2

Rüdiger E. Scharf1,2

1 Division of Clinical and Experimental Haemostasis, Hemotherapy and Transfusion Medicine, University Blood Center, and Haemophilia Comprehensive Care Center, Institute of Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Medical Center, Düsseldorf, Germany
2 Biological Medical Research Center, Heinrich Heine University, Düsseldorf, Germany

Hämostaseologie 2018;38:211–222.

Abstract

Platelet signal transduction is the focus of this review. While ‘classic’ platelet signaling through G protein–coupled receptors in response to fluid-phase agonists has been extensively studied, signaling mechanisms linking platelet adhesion receptors such as GPIb-IX-V, GPVI and α2β1 to the activation of αIIbβ3 are less well established. Moreover, ‘non-haemostatic’ pathways can also activate platelets in various settings, including platelet–immune or platelet–tumour cell interactions, platelet responses to neutrophil extracellular traps, or stimulation by microbial pathogens. Genetically determined integrin variants can modulate platelet function and increase thrombogenicity. A typical example is the Pro33 (HPA-1b) variant of αIIbβ3. Recent advances in the genotype–phenotype relation of this prothrombotic variant and its impact on outside-in signaling will be reviewed.

Keywords
► platelet signaling
► integrin αIIbβ3
► G protein–coupled receptors
► calcium mobilization

Introduction

The process of transforming integrin αIIbβ3 on the platelet plasma membrane into a competent receptor for soluble fibrinogen, von Willebrand factor (vWF), and other fluid-phase adhesive proteins is one of the major issues in platelet biology. Conversely, in clinical settings, inhibition of the αIIbβ3 activity or function is a main target of antiplatelet treatment. Activation of αIIbβ3 also represents the ‘final common pathway’ in platelet responses to a variety of stimuli. Importantly, αIIbβ3 is capable of signaling bidirectionally. Thus,
signals to and from the integrin can occur. Regulation of αIIbβ3 activation is induced from the platelet interior (‘inside-out’ signaling), while αIIbβ3, by interacting with the platelet exterior, can control distinct platelet functions (‘outside-in’ signaling).

**Platelet Signaling**

**Second Messengers in Platelet Activation**

Cellular activation involves enzymes, substrates, and co-factors engaged in specific protein–protein and protein–lipid interactions. Fundamentals of platelet ‘second messengers’—a term introduced by E.W. Sutherland (Nobel Prize in 1971)—have been known for many years and are, therefore, only briefly summarized. Most soluble agonists induce platelet activation through receptors coupled to distinct heterodimeric guanine (G) nucleotide-binding proteins, commonly designated G protein–coupled receptors (GPCR), mediating inside-out signaling. GPCR engagement triggers activation of phospholipase C (PLC). PLC in turn hydrolyses membrane-associated phosphatidylinositol-4,5-diphosphate, thereby producing second messengers such as inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). A discussion of the different G protein species (→ Table 1), PLC isoforms (β or γ) and signaling pathways downstream of GPCR is beyond the scope of this contribution. The reader is referred to a comprehensive review by Offermanns.1

**Calcium mobilization.** IP3 contributes to Ca2+ mobilization from internal stores, while DAG promotes transmembrane Ca2+ uptake. The net result of these processes is a rise in cytosolic Ca2+ concentration within less than 10 seconds following platelet stimulation by α-thrombin or collagen.2

Upon platelet stimulation by α-thrombin, two distinct PAR-dependent transient responses have been found: an early, short-lived response (mediated by PAR-1), followed by a more prolonged Ca2+ signal (mediated by PAR-4).3 A similar pattern of Ca2+ oscillations was observed during platelet adhesion onto immobilized VWF4 and upon ADP- or collagen-induced platelet activation in the presence of high shear.5,6 With regard to the synergy between α2β1 and GPVI, discussed in Part 1 of this review, it has been shown that α2β1 can induce GPVI-independent Ca2+ signaling; however, longer-lasting Ca2+ oscillations require reinforcement by GPVI through transmembrane ion flux.6

---

**Table 1** Receptors, agonists, ligands, and signaling pathways in platelet thrombus formation. Modification of a table taken from Ruggeri57; Data adapted from Offermanns.71

<table>
<thead>
<tr>
<th>Phase of response</th>
<th>Substrates, agonists, ligands</th>
<th>Receptors</th>
<th>Signaling pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiation</td>
<td>VWF</td>
<td>GPIb-IX-V</td>
<td>PI3K and others</td>
</tr>
<tr>
<td>Tethering and adhesion</td>
<td>Collagen</td>
<td>GPVI–FcRy, α2β1</td>
<td>Syk/PLCy</td>
</tr>
<tr>
<td>Fibrinogen, fibrin</td>
<td>αIIbβ3 (resting)</td>
<td></td>
<td>Syk/pp125AK</td>
</tr>
<tr>
<td>Fibrinectin</td>
<td>α5β1</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Laminin</td>
<td>α6β1</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Propagation/Extension</td>
<td>α-Thrombin</td>
<td>PAR1, PAR4</td>
<td>G0, G12, G/Rho, PLCβ</td>
</tr>
<tr>
<td>Activation</td>
<td>P2Y1</td>
<td>G0 (G12)/Rho, PLCβ</td>
<td></td>
</tr>
<tr>
<td>Thromboxane A2</td>
<td>TPα/β</td>
<td>G0 (G12)/Rho, PLCβ</td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td>α2a-adrenergic</td>
<td>G2/adenyl cyclase</td>
<td></td>
</tr>
<tr>
<td>Serotonin</td>
<td>S-HT2A</td>
<td>G0?</td>
<td></td>
</tr>
<tr>
<td>Aggregation</td>
<td>Fibrinogen, VWF, fibrinectin</td>
<td>αIIbβ3 (activated)</td>
<td>SFK, SHC</td>
</tr>
<tr>
<td>Stabilization</td>
<td>P-selectin</td>
<td>PSGL-1, GPIb-IX-V, others?</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ephrin</td>
<td>EPH kinases</td>
<td>Lyn, Fyn</td>
<td></td>
</tr>
<tr>
<td>CD40 ligand</td>
<td>αIIbβ3 (activated)</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>GAS6</td>
<td>AXL</td>
<td>PI3K, PLCy</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AXL, AXL receptor tyrosine kinase; EPH, ephrin receptor; Fyn, shrinkage-activated tyrosine kinase; GAS6, growth arrest–specific 6; GP, glycoprotein; S-HT2A, serotonin receptor; Lyn, tyrosine kinase; PAR: protease-activated receptor(s); PECAM: platelet-endothelial cell adhesion molecule; PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase C; PSGL-1, P-selectin glycoprotein ligand; Rho (Ras homology): distinct family of GTPases belonging to the Ras superfamily; SFK, Src family of tyrosine kinases; SHC, Src homology domain-containing transforming protein C, an adaptor molecule; Syk, tyrosine kinase; TP, thromboxane receptor; VWF, von Willebrand factor.

Source: Modification of a table taken from Ruggeri.57 Data adapted from Offermanns.1
Effects of calcium mobilization. Apart from triggering aggregation, the increase in cytosolic Ca\(^{2+}\) concentration amplifies or regulates many functions and pathways in platelets. For example, Ca\(^{2+}\) causes a p38 MAP (mitogen-activated protein) kinase-dependent activation of phospholipase A\(_2\), which hydrolyzes membrane phospholipids, leading to the production of arachidonic acid (AA) and TXA\(_2\) synthesis. The conversion of AA into TXA\(_2\) is mediated by cyclooxygenase-1 and thromboxane synthase. TXA\(_2\) functions as a positive feedback mediator during platelet activation. Interestingly, platelet responses to TXA\(_2\) and also to \(\alpha\)-thrombin, at low or intermediate concentrations, are reduced in the absence of ADP receptors (for review, see the article by Offermanns). This observation underlines the importance of ADP as a positive feedback agonist that amplifies the responses by other stimuli, thereby inducing sustained platelet activation.

Conversely, suppression of Ca\(^{2+}\) mobilization by cyclic nucleotides can stabilize platelets in the resting state. An increase in intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels is achieved in either way, by stimulating their synthesis (via cyclic adenylate/guanylate cyclase) or by inhibiting their degradation (via phosphodiesterase, PDE), PGI\(_2\) and NO (see – Fig. 1 in Part 1) inhibit platelet activation using option one, while dipyridamole and several other agents are PDE inhibitors. Negative regulation of platelet activity by cAMP and cGMP and, most importantly, negative control of \(\alpha\)IIb\(\beta\)3 involve the protein kinases A and G (PKA, PKG). Their substrates are the IP\(_3\) receptor and certain signaling proteins.

![Fig. 1](image-url) c-Src-mediated outside-in signaling in HPA-1 variants of \(\alpha\)IIb\(\beta\)3 upon platelet adhesion. c-Src, a tyrosine kinase, is bound to the \(\beta\)3-subunit and interacts co-ordinately with two other tyrosine kinases (Csk and Syk) that are associated with \(\alpha\)IIb\(\beta\)3. c-Src is essential for outside-in signaling upon ligand binding and microclustering of the receptor. (A) Schematic representation of c-Src activation. In the inactive state, c-Src is maintained in a ‘clamped’ conformation through intramolecular interactions and a phosphotyrosine motif at Tyr525 (pY525), indicated on the left. Upon ligation of \(\alpha\)IIb\(\beta\)3 by immobilized fibrinogen, c-Src undergoes a conformational change with dephosphorylation of Tyr525 and trans-autophosphorylation of Tyr418 (pY418) in the activation loop. c-Src is now ‘unclamped’ and fully active to phosphorylate downstream effectors implicated in signaling to the actin cytoskeleton (► Fig. 2). (B) through (D) Activity of c-Src pY418 in platelets adhering onto fibrinogen (Fg), examining both \(\alpha\)IIb\(\beta\)3 isoforms, HPA-1a (Leu33) and HPA-1b (Pro33). (B) Western blots are probed with specific antibodies to c-Src pY418 (upper panel), total c-Src (lower panel), or c-Src pY525 (not shown), quantified densitometrically, and expressed as ratio of c-Src p418 to total c-Src. Representative results of six separate experiments. Washed platelets that were allowed to adhere onto Fg (100 \(\mu\)g/mL) in the absence or presence of added Mn\(^{2+}\). (C) Adherent platelets homozygous for HPA-1b (closed squares in the absence of Mn\(^{2+}\)) exhibit significantly enhanced c-Src pY418 activity as early as 2.5 minutes of incubation time in comparison to HPA-1a platelets (open squares). Throughout, addition of Mn\(^{2+}\) (0.5 or 0.75 mM) increases c-Src pY418 activity substantially more in HPA-1b (closed triangles) than in HPA-1a platelets (open triangles) and (D) peaks at prolonged incubation times. \(p < 0.05\), \(^*\)p < 0.01 (unpaired t-test).
molecules, which, upon phosphorylation at distinct sites, either attenuate platelet responses or maintain platelets in the resting state.8

**Integrin ‘Inside-Out’ versus ‘Outside-In’ Signaling**

Integrins display bidirectional signal transduction.9 Their regulation can be divided into ‘inside-out’ and ‘outside-in’ signaling.8–12 The distinction has primarily been made for experimental reasons.

In platelets, inside-out signal transduction denotes responses that are typically initiated by binding of one or more agonists (such as α-thrombin, TXA2, ADP, or epinephrine) to cognate agonist receptors (GPCRs) on the platelet surface. This interaction in turn stimulates signaling pathways that eventually result in the activation of αIIbβ3, characterized by the conversion from a low-affinity into a high-affinity state and the ability to bind soluble macromolecular ligands. Hence, in this signaling mode, αIIbβ3 is activated by stimulation from the platelet interior.

Outside-in signaling transduction denotes responses initiated by adhesive ligand binding to (and clustering of) the integrin leading to the generation of inward-directed signals that promote further platelet responses (‘post-occupancy’ or ‘post-ligand’ events). The responses regulated by αIIbβ3 include activation of additional integrins, cytoskeletal rearrangements, platelet secretion, and development of platelet procoagulant activity.11 Hence, in this mode, ‘contact-’ or ‘anchorage-dependent’ signaling from the outside induces αIIbβ3 activation. This process requires coordination with signals emanating from other plasma membrane receptors, typically from GPCR.10

Importantly, apart from αIIbβ3, certain adhesion receptors, notably GPIb-IX-V, GPVI, and α2β1, can generate signals and trigger activation, when ligated (‘occupied and/or clustered’) by ECM ligands.8 The mode of how multiple key players orchestrate αIIbβ3 outside-in signaling has recently been discussed in a comprehensive review, summarizing major advances in this field.13

**Signaling Mechanisms Linking Platelet Adhesion Receptors to αIIbβ3 Activation**

The ‘final common pathway’ of the different signaling cascades in platelets is the activation of αIIbβ3, the principal receptor for stable adhesion and aggregation. In recent years, major progress has been made in understanding the complex interactions, by which important biological functions of integrins (including the change in ligand-binding properties) are regulated downstream of GPCRs and platelet adhesion receptors.14

**Signaling through GPIb-IX-V.** The effector mechanisms, through which signaling downstream of VWF-A1 binding to GPIb-IX-V operates, are incompletely explored at present. This is mainly due to the impossibility to separate adhesive and signaling functions of the receptor. However, several major advances have been made.

First, a mechanosensitive domain in GPIbα has recently been identified.15 Consequently, it is postulated that the VWF-A1 link to GPIbα represents a sensor of biomechanical force that in turn, through mechanotransduction, could provide signals to conform the platelet activation response to the haemodynamic conditions of a growing thrombus.16

Second, indirect evidence suggests that clustering of GPIb-IX-V complexes can induce upregulation of the adhesive properties of αIIbβ3 though VWF-dependent signaling, thereby promoting thrombus formation.17 Third, Ruggeri’s and Shattil’s groups have shown that dimeric VWF-A1 can induce signaling through GPIb-IX-V followed by subsequent activation of αIIbβ3.18 Importantly, this response is independent of other receptors and involves sequential actions of c-Src-related tyrosine kinases, Ca2+ oscillations and PI3K/PKC (phosphatidylinositol 3-kinase/protein kinase C).

Fourth, GPIb-IX-V can associate with Fc receptors (FcR), FcR γ-chain and FcγRIIA, containing an immuno-receptor tyrosine-based activation motif (ITAM).19 In analogy to other ITAM-coupled receptors (such as GPVI16), the observation supports the hypothesis that a cross-linking mechanism may be involved in GPIb-IX-V-induced signaling.16 A key feature in this scenario is tyrosine phosphorylation of the ITAM sequence by a c-Src family tyrosine kinase, leading to recruitment and auto-phosphorylation of a Syk family kinase.19 Syk initiates a signaling cascade that culminates in the activation of second messenger generating enzymes (PI3K and PKC) with production of IP3, as discussed. Subsequent binding of IP3 to its receptor on the dense tubular system mobilizes Ca2+ from internal stores and also induces Ca2+ uptake from the external milieu. The resulting transient Ca2+ oscillations in response to ligation of GPIbα by VWF-A1 were recently reviewed in detail by Ruggeri and Mendolicchio.16

**Signaling through GPVI.** This collagen receptor, a member of the immunoglobulin superfamily, is exclusively expressed in megakaryocytes and platelets.20 GPVI undergoes a non-covalent association with the FcR γ-chain that contains the ITAM-bearing signal transducing domain.19 Upon binding to collagen, cross-linking of GPVI induces interaction of the FcR γ-chain with the c-Src family tyrosine kinases Fyn and Lyn, resulting in tyrosine phosphorylation of the ITAM.19 The subsequent signaling pathway is identical to that described earlier. Nießwandt and Watson have extensively studied the function and signaling of GPVI both in men and mice. For details, the reader is referred to comprehensive reviews by these investigators.14,21,22

**Signaling through integrin α2β1.** Ligation of α2β1 by collagen contributes to platelet activation in two ways, indirectly by reinforcing GPVI-collagen interactions and directly by a series of outside-in signaling events that involve c-Src, Syk, SLP-76 (a haematopoietic member of the 76 kDa adapter protein family)23 and PLCγ2.21 Adaptor proteins (APs) are structural and functional ‘linker’ molecules; they lack intrinsic effector functions but contain distinct modular domains, which mediate protein–protein interactions. APs serve as scaffolds, around which effectors and their substrates are assembled into signaling complexes. Of note, the two platelet collagen receptors, GPVI and α2β1, although structurally unrelated, are sharing crucial molecules in their downstream signal transduction.
**Signaling through integrin αIIbβ3.** Among the five integrins (αIIbβ3, αvβ3, α2β1, α5β1, α6β1) expressed in platelets, αIIbβ3 is, with approximately 80,000 copies on the surface of resting platelets, by far the most dominant receptor, both qualitatively and quantitatively (>98% compared with the other platelet integrins). The central role of αIIbβ3 has been subject to several excellent reviews, some of which discuss inside-out signaling pathways downstream of agonist receptors in detail. In fact, this contribution is focused on outside-in signal transduction events.

**αIIbβ3-mediated outside-in signaling** is initiated by specific trans-auto-phosphorylation of the tyrosine kinase c-Src bound via its SH3 domain to the β3 cytoplasmic tail of active αIIbβ3 (Fig. 1). Activation of c-Src is tightly regulated. In its resting state, c-Src is under the control of Csk, another tyrosine kinase that is also associated with αIIbβ3. Csk negatively regulates c-Src activity by phosphorylating Tyr529. Adhesion of αIIbβ3 to immobilized fibrinogen causes Csk to dissociate from αIIbβ3, concomitant with dephosphorylation of Src Tyr529 and phosphorylation of the c-Src activation loop at Tyr418. As indicated by ‘off’ and ‘on’ (Fig. 1A), Csk and c-Src function as molecular switches in this trans-autophosphorylation. A third tyrosine kinase, Syk, involved in this regulation and subsequent signaling, associates with αIIbβ3 after fibrinogen binding (receptor ‘occupancy’).

Upon phosphorylation of the Tyr418 motif, c-Src induces Syk-mediated activation of Vav1 followed by GTP loading on Cdc42 and Rac1 (Fig. 2, inset), which drive lamellipodia formation and platelet spreading. Vav1 belongs to a family of proteins that act as guanine nucleotide exchange factors for small G proteins of the Rho/Rac family. Cdc42 and Rac1 operate as molecular switches in the transduction and amplification of signals from surface receptors to the signaling pathways that drive and regulate platelet function.

Members of the Rho family of GTP-binding proteins (also designated Rho GTPases) are master regulators of the platelet function. Thus, Rho GTPases operate as molecular switches in the transduction and amplification of signals from surface receptors to the signaling pathways that drive and regulate platelet function. In platelets, the c-Src family of kinases (SFKs) phosphorylates a plethora of signaling and/or membrane-associated molecules, of which only a few are depicted here. Two MAP kinases, ERK1 (p44) and ERK2 (p42), are involved in signal transmission to the cytoskeleton. The ERK substrate, MLC kinase, is directly phosphorylated by ERK2. Upon platelet activation, coordinated inhibition of the MLC phosphatase and activation of MLC kinase are required to promote platelet secretion. FAK (see Fig. 5) is another important substrate of SFKs downstream of αIIbβ3 in response to receptor clustering. Abbreviations: ERK, extracellular signal-regulated kinases; FAK, focal adhesion kinase; MAP, mitogen-activated protein; MLC, myosin light chain; sCD40L, soluble CD40 ligand; SFK, Src family (tyrosine) kinases. Inset: modification of a figure taken from Huveneers and Danen.
are members of the Rho/Rac family. Importantly, these GTPases are GTP-binding proteins, which cycle between inactive GDP-bound and active GTP-bound states and thus function as molecular switches. Several lines of evidence exist that RhoA activity is required to maintain stable interactions of αIIbβ3 with ECM components under high-shear conditions.\textsuperscript{29} Subsequent steps in this signaling cascade involve several molecular adapter proteins (SLP-76; ADAP, adhesion and degranulation-promoting protein; and c-Cbl) as well as PLCγ2, resulting in platelet spreading on immobilized fibrinogen. Thereby, c-Src forms a complex with tyrosine-phosphorylated focal adhesion kinase (FAK). Other substrates implicated in signaling to the actin cytoskeleton will be discussed in the section on integrin variants.

It has become evident that this pathway initiated by direct interaction of αIIbβ3 with c-Src is crucial for normal haemostasis. Thus, a β3-integrin mutant that can bind to its ligand but is impaired in outside-in signaling fails to rescue the β3-integrin knockout phenotype in mice, which is characterized by severe bleeding, similar to consequences of mutations in the ITGβ3 gene in humans, causing Glanzmann thrombasthenia.\textsuperscript{30}

**Platelet Signaling through G Protein–Coupled Receptors**

As outlined in the Part 1 of this series, initial adhesion of platelets to vascular lesions is largely independent of soluble agonists, most of which induce G protein–mediated signaling. By contrast, subsequent recruitment of flowing platelets into a growing thrombus requires diffusible excitative mediators. The same holds true for adherent platelets to induce full activation, irreversible adhesion, and stable platelet-to-platelet cohesion/aggregation. In addition to thrombin, the second wave of platelet stimulation is caused by dense granule secretion of ADP and serotonin along with the synthesis and release of TXA2.

Three major signaling pathways induce platelet activation through GPCR. Initiation is achieved by activating the G proteins Gq, Gi2/13, and Gi (→ Table 1). Downstream events by this inside-out signaling process involve a wide array of molecular species, including kinases, phosphatases and adaptor proteins. The concerted action of multiple agonist receptors and multiple routes of activation ensures that initial responses to individual agonists are amplified to support irreversible platelet aggregation. For further information, the reader is referred to comprehensive reviews.\textsuperscript{1,14}

**Platelet Agonists Functioning through ‘Non-haemostatic Pathways’**

Platelets do not function exclusively in haemostasis or induce thrombotic complications in atherosclerosis. It is becoming increasingly evident that platelets are actively involved in inflammatory processes, host defence, innate and adaptive immunity, and cancer progression.\textsuperscript{31,32} Thus, platelets can actively contribute to communication with and/or co-regulation of multiple cell types. Those interactions may result in mutual cellular activation, whereby platelets often utilize (or ‘misuse’) their adhesion receptors that normally function in haemostasis.

Platelet–immune cell interactions are manifold. For example, GPlbox on matrix-adherent platelets facilitates recruitment of neutrophils through binding to leukocyte integrin αMβ2 (Mac-1).\textsuperscript{33} Microparticles bearing Mac-1 and derived from stimulated neutrophils can bind to platelets via GPlbox and promote platelet P-selectin expression and αIIbβ3 activation.\textsuperscript{33} Stimulated platelets secrete several important cyto- and chemokines\textsuperscript{34} and promote activation of neutrophils or cause activation of dendritic cells, thereby increasing antigen presentation to T cells.

Neutrophil extracellular traps (NETs) are another example of immune cell–platelet interactions. NETs are composed of DNA, histones and serine proteases and are part of the antibacterial defence mechanism\textsuperscript{35} but can also promote tumour growth and metastasis.\textsuperscript{36} NETs form a meshwork (‘NETosis’), thereby providing a scaffold and stimulus for the binding of platelets and thrombus growth.\textsuperscript{37} Conversely, host DNases, degrading NETs, protect from thrombotic vascular occlusions and organ failure in septicemia.\textsuperscript{38}

Platelets may directly interact with histones, in part through platelet toll-like receptors, TLR2 and TLR4.\textsuperscript{39} Moreover, several histones can act as substrates for platelet adhesion and spreading or stimulate fibrinogen binding to αIIbβ3. Platelet activation triggered by histones is mediated by ERK (extracellular signal–regulated kinases) via the PI3K/AKT pathway (PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B) and the p38 MAPK pathway (p38, belonging to the MAP kinases [MAPKs]).\textsuperscript{40} Among other examples, these multifaceted interactions illustrate that platelets are involved in many processes beyond haemostasis.

**Platelet Signaling in Integrin αIIbβ3 Variants**

Platelet membrane GPs are highly polymorphic. This also holds true for αIIbβ3 and α2β1. The human platelet antigen-1 (HPA-1) polymorphism in αIIbβ3 arises from a Leu→Pro exchange at residue in the β3-subunit, resulting in Leu33 (HPA-1a) or Pro33 (HPA-1b) isoforms (→ Fig. 3).

**Impact of the HPA-1 Polymorphism on αIIbβ3**

Clinical association studies, using a case-only design, have shown that patients with coronary artery disease (CAD) who are carriers of the HPA-1b allele experience their myocardial infarction five years earlier in life than CAD patients who are HPA-1b negative\textsuperscript{41,42} and that, upon saphenous-vein coronary bypass grafting, HPA-1b is a hereditary risk factor for bypass occlusion, myocardial infarction, or early death (<30 days) after bypass surgery.\textsuperscript{43} These results suggest that the Leu→Pro exchange may modulate functional properties of αIIbβ3, resulting in a prothrombotic integrin variant.\textsuperscript{44} Indeed, in subsequent experiments under flow-dynamic conditions, it was documented that Pro33 (HPA-1b) platelets and αIIbβ3 (Pro33)-transfected cells display a prothrombotic
phenotype, as characterized by increased adhesion activity, increased resistance of adherent transfectants to high shear, increased aggregate/thrombus formation, and increased outside-in signaling.

Recently, the molecular nature of this prothrombotic integrin variant was elucidated. Using Förster’s energy transfer and molecular dynamics simulations, evidence was provided that the Leu-Pro exchange weakens interdomain interactions at the β3-subunit genu located between the PSI and EGF-1/EGF-2 domains (Fig. 3). This effect alters the structural dynamics of αIIbβ3 to a more bent and splayed state, which results in a conformation that is closer to the active one, promoting the fully active state and fostering the prothrombotic phenotype of Pro33 platelets.

Impact of the HPA-1 Polymorphism on c-Src Activity

Platelet adhesion onto immobilized fibrinogen causes a prompt activation of c-Src (Fig. 1B). As less than 3 minutes of incubation, adherent platelets homozygous for HPA-1b (Pro33) exhibit a significantly enhanced c-Src activity when compared with HPA-1a (Leu33) platelets. Prolonged incubation has no effect on this difference between the two isoforms of αIIbβ3, both of which display a nearly constant phosphorylation rate (Fig. 1C). By contrast, pretreatment of platelets with Mn²⁺, in a dose-dependent manner (data not shown), largely enhances the c-Src activity of the Pro33 variant but causes a significant lower increase in phosphorylating the specific Tyr418 motif of the Leu33 isoform (Fig. 1C, D).

Metal ions are required for the binding of fibrinogen and VWF to β3 integrins, and using Mn²⁺ is an established experimental tool to induce an active ‘unbent’ conformation of αIIbβ3 by acting via three metal ion binding sites in the β3-subunit, notably MIDAS (metal ion-dependent adhesion site). Based on the molecular dynamics analysis, demonstrating an allosteric shift of the Pro33 variant toward an active integrin, it is now possible to provide a concise explanation for the observed differences in c-Src activation between the two isoforms of αIIbβ3.

Impact of the HPA-1 Polymorphism on ERK1/ERK2 Activity

Among the mitogen-activated protein (MAP) kinases, two extracellular signal-regulated kinases, ERK1 (p44) and ERK2 (p42), are involved in signal transmission to the cytoskeleton, both of which are substrates of upstream Rho GTPases. Activation of ERK1/ERK2 is induced by tyrosine/threonine (Tyr/Thr) phosphorylation. In comparison to Leu33, adherent Pro33 platelets display substantially greater ERK2 activation (Fig. 4). Protein phosphatase-1 (PP1), a potent and selective inhibitor of the c-Src family

**Fig. 3 Model of αIIbβ3 and location of the Leu33→Pro33 exchange (HPA-1 polymorphism).** Depicted are the extracellular domains of the α- and β-subunits in the bent conformation of the integrin. The ‘head’ of the receptor is formed by the β-propeller of the αIIb-subunit (shown in blue) and the βA domain of the β3 subunit (shown in magenta); the ‘legs’ are formed by the thigh and calf domains (αIIb subunit) and four EGF domains together with the β-tail domain (β3-subunit). The PSI (plexin–semaphorin–integrin, shown in green) domain with the adjacent hybrid and EGF-1 domains are part of the β3 ‘genu’ (indicated by blue dashed lines). The β3 genu is of particular interest in integrin activation. The EGF domains (EGF1 through EGF4) are shown in purple, yellow, light blue or ochre, respectively. **Enlargement:** location of the Leu→Pro exchange at residue 33 in the genu of the β3-subunit ecto domain. Of note, although located >80 Å away from extracellular binding sites and >90 Å away from the transmembrane domains, the Pro33 substitution has a strong impact on the structural and functional stability of the entire molecule. The dynamic conformational equilibrium of αIIbβ3 is allosterically shifted to a structural state that is closer to the active conformation. Thus, the fully active state of αIIbβ3 is promoted, thereby fostering the prothrombotic phenotype of Pro33 (HPA-1b) platelets.

**Fig. 1A** Platelet adhesion onto immobilized fibrinogen causes a prompt activation of c-Src (→Fig. 1B). As less than 3 minutes of incubation, adherent platelets homozygous for HPA-1b (Pro33) exhibit a significantly enhanced c-Src activity when compared with HPA-1a (Leu33) platelets. Prolonged incubation has no effect on this difference between the two isoforms of αIIbβ3, both of which display a nearly constant phosphorylation rate (→Fig. 1C). By contrast, pretreatment of platelets with Mn²⁺, in a dose-dependent manner (data not shown), largely enhances the c-Src activity of the Pro33 variant but causes a significant lower increase in phosphorylating the specific Tyr418 motif of the Leu33 isoform (→Fig. 1C, D).

**Fig. 1B** Metal ions are required for the binding of fibrinogen and VWF to β3 integrins, and using Mn²⁺ is an established experimental tool to induce an active ‘unbent’ conformation of αIIbβ3 by acting via three metal ion binding sites in the β3-subunit, notably MIDAS (metal ion-dependent adhesion site). Based on the molecular dynamics analysis, demonstrating an allosteric shift of the Pro33 variant toward an active integrin, it is now possible to provide a concise explanation for the observed differences in c-Src activation between the two isoforms of αIIbβ3.

**Fig. 1C, D** Protein phosphatase-1 (PP1), a potent and selective inhibitor of the c-Src family...
Rho GTPases such as Rac1 (by enhanced signal transduction through platelet exterior to the platelet cytoskeleton. Others, signal transduction to ERK2. Activation in both platelets homozygous for either genotype of α associated protein kinase ROCK. Western blots are probed with a specific anti-phospho-antibody to pERK2 or an antibody to ERK1/2 and quantified by densitometry; results are expressed as ratio of ERK2 to total ERK. Pro33 platelets display a twofold higher ERK2 phosphorylation rate than Leu33 platelets. Rho kinase inhibitors abrogate pERK activity in either isoform. Experimental conditions: fibrinogen (100 μg/ml); incubation at 37°C; adhesion time of 10 minutes; results (mean ± SEM) of three experiments in each setting.

**Conclusions and Perspectives**

Platelets respond to a variety of activating and inhibitory stimuli, both of which may have a strong impact on whether or not an occluding thrombus will form. The versatility of platelet reactions to environmental conditions may also explain why the consequences of inhibiting specific platelet agonists can differ in physiological haemostasis and pathological thrombosis.

The type of arterial vessel(s) involved, local dysfunction of endothelial cells, possibly in association with inflammatory processes, exposure of tissue factor, and/or subendothelial extracellular matrix proteins (such as highly reactive collagens) are important determinants that will enhance platelet thrombogenicity. For example, circulating tissue factor co-localizes at the site of a developing thrombus and contributes substantially to the recruitment and activation of circulating platelets through the generation of α-thrombin. Thus, the nature and extent of a vascular lesion may influence the amount and activity of tissue factor and, consequently, the extent and growth rate of a forming platelet–fibrin thrombus. Moreover, local increase in blood velocity with resulting increase in shear stress at sites of stenosed arteries will also influence platelet reactivity. At the apex of a severely occluded coronary artery, shear rates might exceed 50,000 per second. High shear stress may enhance platelet reactivity through the VWF-A1/GP Ib-IX-V axis of platelet adhesion and activation, and possibly through αIIbβ3.

The aspects of platelet responses to vascular injury discussed here may be modified by genetic variations in the
many proteins involved in adhesion, activation, and aggregation. This is especially true for platelet receptors, as illustrated by prothrombotic integrin variants such as Pro33 (HPA-1b) of \( \alpha_{IIb}\beta_3 \) or \( \alpha_2\beta_1 \). Search for polymorphisms in the corresponding genes, \(^{62}\) characterization of the genotype–phenotype relationship, \(^{50}\) and assessment of critical genotypes and their correlation to thrombotic events\(^{42,43,61}\) may prove useful in the identification and stratification of patients at risk and in the development of suitable targets for pharmacological intervention.\(^{57}\)

Disclosures
The author states that he has no conflict of interest.

Acknowledgment
Work from the author’s laboratory that is cited here was supported by grants from the German Research Council (DFG; Scha 358/1–1 to 3; 358/2–2; 358/3–1; Collaborative Research Center, SFB 612, Project B2). The author is grateful to members of his laboratory and to Drs. Z.M. Ruggeri, S.J. Shattil and H. Gohlke for fruitful discussions.

The Biological Medical Research Center, Heinrich Heine University, Düsseldorf, Germany, and the NRW Research School BioStruct ‘Biological Structures in Molecular Medicine and Biotechnology’ provided additional funding.

References

Fig. 5 Effect of high shear on platelet c-Src and FAK activity in comparison to static condition. Focal adhesion kinase (FAK) is a substrate of Src family kinases (SKFs) downstream of \( \alpha_{IIb}\beta_3 \), forming SKF-FAK complexes within focal adhesions of platelets in response to ligand-induced integrin clustering. Upon activation of FAK by autophosphorylation at Tyr397, the SKF-FAK complexes induce phosphorylation of additional tyrosine residues in FAK that serve as ‘docking sites’ for downstream effectors. Washed human platelets incubated on fibrinogen are left under static conditions or exposed to shear rates of 500 or 5,000 per second, respectively, using a cone-plate viscometer. Specific phosphorylation of c-Src (pY418) and FAK (pY397) is determined by Western blotting and quantified densitometrically (see legend to \( \Rightarrow \) Fig. 3, except that \( \beta_3 \) is used as reference for quantitation). Both c-Src (A) and FAK (B) exhibit specific phosphorylation under static condition. Exposure of adherent platelets to a shear rate of 500 per second does not increase phosphorylation activities (not shown), whereas high shear rates (5,000 per second) induce an increase in c-Src pY418 and FAK pY397 activities. Under static and high shear conditions, Pro33 platelets (coloured columns) exhibit higher phosphorylation rates of both kinases than Leu33 platelets (light grey columns). By contrast to c-Src, in the absence of fibrinogen, platelets incubated over a BSA matrix and subsequently exposed to high shear (for up to 10 minutes) display a ninefold increase in pY397 activity in a time-dependent manner, as compared with static conditions. This observation indicates that FAK signaling can be induced by shear stress, whereas c-Src activation appears to be predominantly ligand dependent in adherent platelets both under static and high-shear conditions. Addition of abciximab inhibits c-Src and FAK signaling both under static and shear conditions. The blots are representative of five separate experiments in each setting. Experimental conditions: fibrinogen (100 μg/mL); incubation at 37°C; adhesion time of 10 minutes; exposure time to shear of 2 minutes, unless otherwise indicated.
Gyenes M, Hasse M, Stoldt VR, El-Khattouti A, Huynh KC, Scharf RE. Enhanced outside-in signaling through the prothrombotic Pro33 variant of integrin αIIbβ3 in adherent platelets under static and flow dynamic conditions. Blood 2011;118(21):2199


Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100(08):2787–2792


